Total Payments
$184,113
2024 Payments
$126.95
Companies
15
Transactions
183
Medicare Patients
1,585
Medicare Billing
$201,494
Payment Breakdown by Category
Other$103,552 (56.2%)
Consulting$50,920 (27.7%)
Travel$25,521 (13.9%)
Food & Beverage$3,988 (2.2%)
Education$132.05 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $103,552 | 46 | 56.2% |
| Consulting Fee | $50,920 | 14 | 27.7% |
| Travel and Lodging | $25,521 | 64 | 13.9% |
| Food and Beverage | $3,988 | 56 | 2.2% |
| Education | $132.05 | 3 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $55,704 | 35 | $0 (2020) |
| Celgene Corporation | $53,677 | 43 | $0 (2020) |
| Amgen Inc. | $27,448 | 34 | $0 (2019) |
| Janssen Biotech, Inc. | $14,619 | 25 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $10,629 | 8 | $0 (2019) |
| Kite Pharma, Inc. | $6,630 | 13 | $0 (2022) |
| Janssen Scientific Affairs, LLC | $5,911 | 7 | $0 (2019) |
| Gilead Sciences, Inc. | $4,715 | 8 | $0 (2020) |
| Incyte Corporation | $2,185 | 1 | $0 (2020) |
| PFIZER INC. | $2,022 | 3 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $126.95 | 2 | Janssen Biotech, Inc. ($126.95) |
| 2023 | $150.00 | 1 | BeiGene USA, Inc. ($150.00) |
| 2022 | $8,730 | 15 | Kite Pharma, Inc. ($6,630) |
| 2020 | $24,902 | 15 | Takeda Pharmaceuticals U.S.A., Inc. ($15,446) |
| 2019 | $88,492 | 82 | Takeda Pharmaceuticals U.S.A., Inc. ($30,969) |
| 2018 | $53,627 | 56 | Celgene Corporation ($20,737) |
| 2017 | $8,085 | 12 | Novartis Pharmaceuticals Corporation ($7,104) |
All Payment Transactions
183 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/08/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $57.67 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $69.28 | General |
| Category: Oncology | ||||||
| 12/10/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Oncology | ||||||
| 11/10/2022 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 08/24/2022 | Kite Pharma, Inc. | Yescarta (Drug) | Consulting Fee | Cash or cash equivalent | $4,490.00 | General |
| Category: CELLT | ||||||
| 08/24/2022 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $96.00 | General |
| Category: CELLT | ||||||
| 08/24/2022 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $46.00 | General |
| Category: CELLT | ||||||
| 08/24/2022 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $27.50 | General |
| Category: CELLT | ||||||
| 08/24/2022 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $22.05 | General |
| Category: CELLT | ||||||
| 08/24/2022 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $6.59 | General |
| Category: CELLT | ||||||
| 08/24/2022 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $4.99 | General |
| Category: CELLT | ||||||
| 08/13/2022 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $49.84 | General |
| Category: CELLT | ||||||
| 08/13/2022 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $49.61 | General |
| Category: CELLT | ||||||
| 08/13/2022 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $24.80 | General |
| Category: CELLT | ||||||
| 08/12/2022 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $981.07 | General |
| Category: CELLT | ||||||
| 08/12/2022 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $541.80 | General |
| Category: CELLT | ||||||
| 08/12/2022 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $289.78 | General |
| Category: CELLT | ||||||
| 06/01/2022 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $99.64 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 07/25/2020 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $2,185.00 | General |
| 06/01/2020 | Janssen Biotech, Inc. | DARZALEX (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $500.00 | General |
| Category: Oncology | ||||||
| 04/30/2020 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,620.00 | General |
| Category: ONCOLOGY | ||||||
| 04/15/2020 | Celgene Corporation | Revlimid (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $565.00 | General |
| Category: Hematology | ||||||
| 03/13/2020 | Celgene Corporation | Revlimid (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,130.00 | General |
| Category: Hematology | ||||||
| 03/12/2020 | Celgene Corporation | Revlimid (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,673.00 | General |
| Category: Hematology | ||||||
| 03/12/2020 | Celgene Corporation | Revlimid (Drug) | Travel and Lodging | Cash or cash equivalent | $1,251.18 | General |
| Category: Hematology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 157 | 218 | $124,095 | $19,632 |
| 2022 | 9 | 412 | 595 | $157,441 | $45,756 |
| 2021 | 9 | 500 | 848 | $200,354 | $70,895 |
| 2020 | 11 | 516 | 891 | $212,761 | $65,211 |
Total Patients
1,585
Total Services
2,552
Medicare Billing
$201,494
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 32 | 43 | $25,413 | $4,424 | 17.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 40 | 61 | $25,319 | $4,300 | 17.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 38 | $23,104 | $3,517 | 15.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 25 | 25 | $19,700 | $3,088 | 15.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 17 | 17 | $10,440 | $1,760 | 16.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 11 | $13,902 | $1,484 | 10.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 19 | 23 | $6,217 | $1,059 | 17.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 135 | 260 | $54,342 | $17,974 | 33.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 52 | 72 | $22,730 | $7,370 | 32.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 92 | 102 | $17,994 | $4,754 | 26.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 23 | 23 | $15,017 | $3,578 | 23.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 26 | 26 | $16,442 | $3,299 | 20.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 24 | 24 | $9,496 | $2,536 | 26.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 26 | 26 | $10,234 | $2,162 | 21.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 18 | 37 | $5,365 | $2,072 | 38.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 16 | 25 | $5,821 | $2,010 | 34.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 188 | 403 | $81,804 | $28,723 | 35.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 75 | 144 | $40,806 | $16,432 | 40.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 31 | 66 | $13,530 | $5,411 | 40.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 25 | 26 | $13,130 | $4,132 | 31.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 28 | 28 | $11,900 | $3,952 | 33.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 74 | 82 | $14,350 | $3,920 | 27.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 35 | 35 | $11,375 | $3,677 | 32.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 23 | 43 | $6,235 | $2,453 | 39.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 21 | 21 | $7,224 | $2,196 | 30.4% |
About Dr. Shahzad Raza, MD
Dr. Shahzad Raza, MD is a Hematology & Oncology healthcare provider based in Kansas City, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/25/2012. The National Provider Identifier (NPI) number assigned to this provider is 1962765982.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Shahzad Raza, MD has received a total of $184,113 in payments from pharmaceutical and medical device companies, with $126.95 received in 2024. These payments were reported across 183 transactions from 15 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($103,552).
As a Medicare-enrolled provider, Raza has provided services to 1,585 Medicare beneficiaries, totaling 2,552 services with total Medicare billing of $201,494. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Kansas City, MO
- Active Since 06/25/2012
- Last Updated 05/03/2017
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1962765982
Products in Payments
- Revlimid (Drug) $53,510
- NINLARO (Drug) $43,968
- DARZALEX (Biological) $20,473
- Nplate (Biological) $15,869
- TASIGNA (Drug) $7,104
- Yescarta (Drug) $6,630
- Kyprolis (Biological) $6,135
- ICLUSIG (Drug) $2,560
- Pomalyst (Drug) $166.94
- BRUKINSA (Drug) $150.00
- VYXEOS (Drug) $121.12
- VELCADE (Drug) $110.25
- ZEPZELCA (Drug) $99.64
- TEGSEDI (Drug) $79.67
- CARVYKTI (Drug) $57.67
- Avastin (Biological) $12.05
- BESPONSA (Biological) $10.90
- BESPONSA (Drug) $10.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Kansas City
Dr. Suman Kambhampati, Md, MD
Hematology & Oncology — Payments: $281,918
Hematology & Oncology $281,918
Joseph Mcguirk, D.o, D.O
Hematology & Oncology — Payments: $129,700
Hematology & Oncology $129,700
Dr. Stephanie Graff, M.d, M.D
Hematology & Oncology — Payments: $120,151
Hematology & Oncology $120,151
Jaswinder Singh, Md, MD
Hematology & Oncology — Payments: $86,702
Hematology & Oncology $86,702
Dr. Tara Lin, Md, MD
Hematology & Oncology — Payments: $24,114
Hematology & Oncology $24,114
Maureen Sheehan, M.d, M.D
Hematology & Oncology — Payments: $18,955
Hematology & Oncology $18,955